$27.66
+3.51 (+14.53%)
Open$24.30
Previous Close$24.15
Day High$29.49
Day Low$23.49
52W High$71.50
52W Low$8.73
Volume—
Avg Volume1.97M
Market Cap1.51B
P/E Ratio—
EPS$-3.48
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
-36.7% upside
Current
$27.66
$27.66
Target
$17.51
$17.51
$11.65
$17.51 avg
$27.07
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 15.31M | 28.74M | 366.27M |
| Net Income | -189,194,203 | -319,644,795 | 43.81M |
| Profit Margin | -1,236.0% | -1,174.2% | 12.0% |
| EBITDA | -151,838,709 | -270,784,256 | 53.48M |
| Free Cash Flow | — | — | 19.66M |
| Rev Growth | -46.7% | -46.7% | -4.9% |
| Debt/Equity | 2.63 | 2.63 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |